Leukemia

CD13/aminopeptidase N involvement in dendritic cell maturation
TO THE EDITOR
Recently it has been shown that CD13/aminopeptidase N (APN) is involved in the development of dendritic cells (DC) and macrophages from cord blood CD34 + cells. 1 More specifically, CD13 expression was positively correlated with cell proliferation, and inhibition of CD13/APN resulted in apoptosis.
Previously, we have reported expression of CD13/APN by DC in the human lung, 2 as well as by various populations of mouse DC. 3, 4 Given the implication of CD13/APN activity in a variety of cellular functions and the prominent expression by DC, we approached the question of whether CD13/APN is functionally involved with DC maturation. To test this, we cultured purified human monocytes in culture fluid with granulocyte-monocyte colony-stimulating factor (GM-CSF) and interleukin (IL)-4 for 5 days, resulting in the development of CD1a-positive immature DC. 5 These cultures were performed in the absence or presence of CD13/APN inhibitors: the potent and CD13/APN-specific inhibitor leuhistin and the less potent inhibitor bestatin (both 10 −3 M). As an additional control, monocytes were cultured for 5 days in culture fluid without GM-CSF and IL-4. Subsequently, the cells were immunophenotyped by flow cytometry and viability of the cells was determined by propidium iodide exclusion.
After 5 days of culture with GM-CSF and IL-4, in either in or not in the presence of CD13/APN inhibitors, two main cell populations could be distinguished on scatter characteristics (in addition to contaminating lymphocytes): one population with high forward and side scatter and one population with low forward scatter and low/intermediate side scatter (Figure 1a ). Using propidium iodide it appeared that the population with high scatter characteristics comprised mainly viable cells (Ͼ80%), whereas the population with low forward scatter had a low viability (Ͻ30%). In the absence of CD13/APN inhibitors, the high scatter population comprised approximately 50% of the cells (Figure 1b) . Immunophenotyping of this population showed that these cells expressed CD1a, HLA-DR, CD13, and CD80, but almost lacked CD14 expression (Figure 2a) , which is consistent with the development of immature DC. Interestingly, when leuhistin was added to the culture, the development of immature DC was significantly inhibited and this was accompanied by an increase in the low scatter population, ie dead cells (Figure 1b) . It is unlikely that this is due to nonspecific cytotoxicity of leuhistin, as contaminating lymphocytes were not affected. Addition of bestatin during the DC culture did not affect the relative composition of the two main cell populations ( Figure 1b ). As such, this finding of increased cellular death induced by blockade of CD13/APN by potent inhibitors is in accordance with the observation that inhibition of CD13/APN resulted in apoptosis. 1 Addition of leuhistin to the DC culture, however, not only affected the development of the high scatter population, but also affected the immunophenotype of these cells as compared to cells cultured without CD13/APN inhibitors. Addition of leuhistin strongly reduced the percentage CD1a and CD80 expressing cells, which was accompanied by a strong reduction in fluorescence intensity of the positive cells. In contrast, the percentage of CD14 expressing cells was significantly increased (Figure 2 ). The immunophenotype of these cells resembled the immunophenotype of monocytes cultured in culture fluid without the maturation-inducing factors GM-CSF and IL-4. These cells expressed CD14, HLA-DR, CD13, and low levels of CD80, but did not express CD1a (Figure 2 ). Bestatin had similar effects as leuhistin (Figure 2 ), although these were less pronounced, possible due to its lower potency. Under all culture conditions, CD13/APN was present on 100% of the large scatter population, but the level of expression was strongly increased when APN inhibitors were added to Effect of CD13/APN inhibition on DC development. (a) Typical forward scatter vs side scatter dot plot of monocytes cultured for 5 days in the presence of GM-CSF and IL-4. 5 Two electronic gates were defined: one gate on the high scatter population (mostly viable cells; R1) and one gate on the low scatter population (mostly nonviable cells; R2). (b) Percentage of cells present in R1 and R2 after a 5 day culture of monocytes in culture fluid only (black bars) or culture fluid supplemented with GM-CSF and IL-4 in the absence (white bars) or presence of bestatin (hatched bars) or leuhistin (dotted bars) (mean ± s.e.m.; n = 3). Total absolute cell numbers did not differ significantly among the different culture conditions. the culture (Figure 2 ). This enhanced expression may reflect a cellular mechanism to circumvent the inhibition of CD13. Overall, the above data indicate that inhibition of CD13/APN prevented the development of immature DC and maintained the cells in a monocyte-like stage. This is further supported by our preliminary finding that addition of CD13/APN inhibitors during the culture of DC from monocytes also significantly reduces the capacity of the resulting cells to stimulate mixed leukocyte reactions.
In conclusion, our results show that CD13/APN plays a role in the development of (immature) DC from monocytes. In addition to its reported effect on cell viability by preventing increased apoptosis induction, 1 we now demonstrate that CD13 also affects the maturation of the DC. The molecular basis of this effect is unclear. Hypothetically, CD13/APN may be involved with the utilization of GM-CSF by the cells, as suggested by Rosenzwajg et al. 1 An alternative, but similarly hypothetical explanation is that CD13/APN activates autocrine or paracrine maturation-promoting peptides. In our view, these are interesting options to be tested given the potent effects of CD13/APN inhibitors on myeloid cell growth and DC maturation.
Figure 2
Effect of CD13/APN inhibition on the immunophenotype of the high scatter population obtained from GM-CSF + IL-4-stimulated monocyte cultures. Cells were immunophenotyped as described previously 6 followed by analysis of the high scatter population. 
TO THE EDITOR
In the prospective study of Dö hner et al, 1 it is described that the deletion of the multidrug resistance protein (MRP1) gene has no prognostic impact in acute myeloid leukemia (AML) patients with an inversion on chromosome 16. These findings are in agreement with the results we recently described, 2 and might be due to the fact that the expression of MRP1 homologues can be upregulated in the case of MRP1 deletion.
MRP1, encoded by the MRP1 gene located on chromosome 16p13, is a member of the superfamily of ATP-binding cassette (ABC) transporters. MRP1 has been shown to transport a broad range of organic substrates, and the expression of MRP1 results in resistance to different classes of chemotherapeutic agents. The MRP family of proteins con-sists of at least six family members, MRP1 to MRP6. 3 However, the role of the MRP1 isoforms is not yet well defined. MRP2, MRP3 and MRP5 have been described to transport chemotherapeutic agents, such as cisplatin, doxorubicin, etoposide and 6-mercaptopurine, but less is known about the transport mechanisms of the proteins MRP4 and MRP6. Another membrane transporter, P-glycoprotein (P-gp) encoded by the MDR1 gene, has also been shown to transport chemotherapeutic drugs. The simultaneous expression and function of both proteins has been shown to be correlated with poor overall survival in AML. 4 A subgroup of patients with AML, most commonly patients with the French-American-British (FAB) classification M4Eo, show the chromosomal inversion 16 inv(16)(p13q22), resulting in a fusion of the MYH11 gene on 16p13 with the CBFB gene on 16q22. Deletion of 1 MRP1 allele has been demonstrated in a subgroup of AML patients with inv(16) and patients with the deletion showed an increased duration of disease-free survival as compared with patients without deletion. 5 However, these findings could not be confirmed in several other studies. In addition the study of Dö hner et al 1 in 25 AML patients with inv(16) also showed no correlation between MRP1 deletion and remission duration.
